Raloxifene manufacturers and suppliers in india

Raloxifene

Properties

Melting point:: 250-253°C

Boiling point:: 728.2±60.0 °C(Predicted)

Density: 1.289±0.06 g/cm3(Predicted)

storage temp.: Desiccate at +4°C

solubility: DMSO: 28 mg/mL, soluble

pka: 8.83±0.15(Predicted)

form: solid

color: light yellow

Water Solubility: 560μg/L at 25℃

LogP: 6.09

Safety Information

Symbol(GHS): GHS08,GHS09,GHS06

Signal word: Danger

Hazard statements: H411-H360-H311

Precautionary statements: P280-P302+P352-P312-P322-P361-P363-P405-P501

WGK Germany: 3

HS Code: 29349990

Use

Raloxifene, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone (Evista), is a benzothiophene derivativethat differs slightly from the triphenylethyleneSERMs. A key structural difference is the carbonyl “hinge”that connects the modified phenolic side chain to the benzothiophenering system. This hinge is the key structural elementthat leads to the differing actions at the ERs.Raloxifene, unlike tamoxifen and toremifene, has antagonistproperties on the endometrium and breast tissue and agonistproperties on bone and the cardiovascular system. The lackof agonist action on endometrial tissue has been suggestedas a reason for the lack of endometrial cancer associatedwith raloxifene use. Raloxifene is approved for the preventionand treatment of osteoporosis in postmenopausalwomen. It has also been investigated for preventing breastcancer in comparison with tamoxifen. Recent studies indicatesthat it has similar effectiveness to tamoxifen, but has apreferable side effect profile.